'A Project Justified by Its Public Relations Value'

The genome. project... seems a ploy to raise money, a project justified by its public relations value, not its scientific value... We stand now at a moment of great opportunity. We have, a low-resolution map of much of the human genome and it is sure to improve. We have the skills to develop clone banks, high-resolution maps and rapid sequencing techniques. We can do what we have always done: each of us can apply these techniques as we see fit. We can distribute our efforts over various exper

Written byDavid Baltimore
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

We stand now at a moment of great opportunity. We have, a low-resolution map of much of the human genome and it is sure to improve. We have the skills to develop clone banks, high-resolution maps and rapid sequencing techniques. We can do what we have always done: each of us can apply these techniques as we see fit. We can distribute our efforts over various experimental systems: mice, flies and simpler organisms. We can set priorities: first, sequence important DNA, such as genes, then focus on discrete chromosomal regions that look most promising. And we can work closely with our colleagues abroad to see that this doesn't become a matter of national pride but rather a world-wide effort to learn all we can about how DNA directs the structure of the biological universe.

Congress, in its last budget, provided money for NIH to develop a program in the structure ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies